

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 451/02, A61K 31/33 C07D 451/06, 207/02, 211/04 C07D 211/68, 409/02	A1	(11) International Publication Number: WO 92/18502 (43) International Publication Date: 29 October 1992 (29.10.92)
(21) International Application Number: PCT/US92/02131 (22) International Filing Date: 24 March 1992 (24.03.92) (30) Priority data: 687,273 18 April 1991 (18.04.91) US (60) Parent Application or Grant (63) Related by Continuation US 687,273 (CON) Filed on 18 April 1991 (18.04.91) (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; Eastern Point Road, Groton, CT 06340-5146 (US).		(72) Inventor; and (75) Inventor/Applicant (for US only) : CHENARD, Bertrand, L. [US/US]; 7 Whaling Drive, Waterford, CT 06385 (US). (74) Agents: LUMB, J., Trevor et al.; Pfizer Inc., Eastern Point Road, Groton, CT 06340-5146 (US). (81) Designated States: AT (European patent), AU, BE (European patent), BR, CA, CH (European patent), CS, DE (Utility model), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), NO, PL, RU, SE (European patent), US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PRODRUG ESTERS OF PHENOLIC 2-PIPERIDINO-1-ALKANOLS (57) Abstract Phenolic prodrug esters of certain 1-(hydroxyphenyl)-2-piperidino-1-alkanol derivatives, which are useful in the treatment of stroke, traumatic head injury and CNS degenerative disease; and intermediates useful in their synthesis.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TC	Togo
DK	Denmark			US	United States of America

-1-


PRODRUG ESTERS OF
PHENOLIC 2-PIPERIDINO-1-ALKANOLS

The present invention is directed to prodrug
5 esters of phenolic 2-piperidino-1-alkanols, as depicted
by the formulas (I) and (II), below; to pharmaceutical
compositions thereof; to a method of treating stroke,
traumatic head injury, or a CNS degenerative disease
therewith; and to ketone intermediates of the
10 formulas (III) and (IV), below, which are useful in
their synthesis.

The phenolic compounds from which the present
compounds derive are disclosed in my International
Applications Published Under the Patent Cooperation
15 Treaty, International Publication Nos. WO 90/14087 and
WO/14088, both published on November 29, 1990, and
hereby incorporated by reference. These phenolic
compounds are of the formulas



and




-2-

wherein A and B are taken separately and A is hydrogen and B is hydroxy, or A and B are taken together and are oxygen (forming a carbonyl group); and the groups R, E, Y and Y¹ are as defined below for the corresponding ester derivatives of the formulas (I), (II), (III) and (IV).

The compounds of the formulas (A) and (B) wherein the groups A and B are taken separately to form a 1-alkanol, like the present compounds of the formulas (I) and (II), generally possess selective antiischemic and excitatory amino acid receptor blocking activity (i.e., a neuroprotective effect) in good measure, while at the same time they have lowered or no significant hypotensive effect.


Ifenprodil, a racemic, so-called dl-erythro compound having the relative stereochemical formula



has been shown to possess antiischemic and excitory aminoacid receptor blocking activity; Gotti et al., J. Pharm. Exp. Therap., v. 247, pp. 1211-21 (1988); Carter et al., loc. cit., pp. 1222-32 (1988). See also French Patent 2546166. However, in ifenprodil, this activity is not selective. Indeed ifenprodil is marketed as a hypotensive agent, a utility shared by a number of close analogs; Carron et al., U.S. Patent 3,509,164; Carron et al., Drug Res., v. 21, pp. 1992-1999 (1971).


-3-

So-called prodrug esters, which in general enhance oral absorption and are hydrolyzed in vivo to form the active component of the ester, have become quite common in the medicinal art. For example, Bundgaard et al.,
 5 J. Med. Chem., v. 32, pp. 2503-7 (1989) have described certain prodrug esters of the type




wherein R^a and R^b are taken separately, R^a is hydrogen or lower alkyl, and R^b is lower alkyl; or R^a and R^b are
 10 taken together with the nitrogen to which they are attached to form, for example, a morpholine or 4-methylpiperazine ring.

The present invention is directed to so-called
 15 pro-drug esters of the formulas




and



-4-


wherein

E is



R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or
 5 (C₂-C₆)alkynyl;


X is phenyl, benzyl, (C₁-C₃)alkoxy, phenoxy or one
 of said groups substituted on aromatic carbon by




p is 1 or 2;

10 R¹ and R² are taken separately and are each
 independently hydrogen or (C₁-C₆)alkyl, or R¹ and R²
 are taken together with the nitrogen to which they are
 attached to form a pyrrolidine, piperidine or
 morpholine ring, or one of said rings substituted by
 15 (C₁-C₃)alkyl;

when either Y and Y¹ or Y² and Y³ are taken
 together, they are




when Y and Y¹ are taken separately,
 20 Y is hydrogen or OH, and Y¹ is




-5-


Y is hydrogen and Y¹ is



when Y² and Y³ are taken separately, and Y² is OH and Y³ is



Y⁹ is



n is 0, 1, 2 or 3;

m is 0, 1, 2, 3 or 4;

10 Q is S or CH=CH;

X¹ is hydrogen, (C₁-C₃)alkyl, (C₁-C₃)alkoxy or halo; and

Z is O, S, SO or SO₂; or


a pharmaceutically-acceptable acid addition salt

15 thereof.


Said acid addition salts include, but are not limited to, those formed with such acids as HCl, H₂SO₄, H₃PO₄, HNO₃, CH₃SO₃H, pCH₃C₆H₄SO₃H, acetic acid, maleic acid and citric acid.

-6-

The preferred compounds are racemic or optically active compounds wherein R is methyl and have $1S^*, 2S^*$ relative stereochemistry:



5 alternatively and equivalently depicted as:



and referred to as $1R^*, 2R^*$ relative stereochemistry. See Rigaudy et al., eds., IUPAC Nomenclature of Organic Chemistry, 1979 Edition, Pergamon Press, New York, 1979, p. 482. Preferred values of X are phenyl, 10 p-(dimethylaminomethyl)phenyl, p-(diethylaminomethyl)-phenyl, m-(diethylaminomethyl)phenyl, p-(piperidinomethyl)phenyl, p-(2-methylpiperidinomethyl)phenyl and p-(morpholinomethyl)phenyl. The preferred position of 15 the XCOO group on the benzene ring is para to the 1-hydroxyalkyl substituent.

The present invention is further directed to pharmaceutical compositions comprising a neuroprotective amount of a compound of formula (I) or (II) and to a 20 method of treating stroke, traumatic head injury or a CNS degenerative disease in man which comprises treatment with a neuroprotective amount of one of said compounds. Said compositions and treatment method include not only the oral route of administration, where absorption from


-7-

the intestinal tract is generally enhanced, but also parenteral routes of administration (e.g., intravenous, intramuscular). The present, intact prodrug esters also generally cross the blood-brain barrier, and


5 further, are capable of hydrolysis in brain tissue once across that barrier. Thus parenteral (as well as oral) administration of these esters can lead to desirable enhancement of active drug levels in the brain.

The present invention is also directed to ketone

10 precursors of the present 1-alkanol derivatives, of the formulas



and



15 wherein

E, R, X, Y and Y¹ are as defined above.

It will be noted that those compounds of the formulas (I) and (II), which are 1-alkanols, possess an asymmetric C-1 carbon, while those wherein R is other

20 than hydrogen possess a second asymmetric center at the C-2 carbon of the alkanol. Similarly, in those compounds of the formulas (III) and (IV) which are 1-alkanones

-8-

wherein R is other than hydrogen possess a C-2 asymmetric carbon. It will be evident to those skilled in the art of organic chemistry, therefore, that such compounds can be resolved into optical isomers showing equal but opposite rotation of plane polarized light. For example, all of these compounds are potentially resolved by fractional crystallization of their diastereomeric acid addition salts formed with an optically active acid; while the alcohols are also potentially resolved by chromatography or fractional crystallization of esters derived by reaction with activated forms of optically active acids or with optically active isocyanates. Thus, the present invention should not be construed as limited to the racemic forms of the present compounds.

15

The present invention is readily carried out. According to the preferred route, the compounds of the above formula (I) and (II) are formed by conventional hydride reduction of a corresponding, already acylated ketone of the above formula (III) or (IV). Hydride reducing agents generally useful in this reduction include lithium aluminum hydride and sodium borohydride. Generally an excess of the hydride reducing agent is employed, but to avoid reduction of the ester group, lithium aluminum hydride is employed at low temperature, e.g., at -50°C to -100°C , conveniently about -78°C , the temperature of a dry ice-acetone bath. In any event, the hydride reduction is carried out in a reaction-inert solvent, such as tetrahydrofuran in the case of lithium aluminum hydride and absolute ethanol in the case of sodium borohydride. With sodium borohydride temperature is less critical, with temperatures in the range of $0-30^{\circ}\text{C}$ being generally preferred.

30

-9-

As used in the preceding paragraph, and elsewhere herein, the expression "reaction inert solvent" refers to any solvent which does not interact with starting materials, reagents, intermediates or products in a manner which adversely affects the yield of the desired product.

Further according to the preferred method of preparing the present compounds of the above formulas (I) and (II), the acylated ketone precursors of the above formulas (III) and (IV) are obtained by acylation of a known ketone derivative, respectively, of the formulas (A) and (B), above, wherein A and B are taken together to form a carbonyl group. Said acylation is readily accomplished by a number of conventional methods which are well known in the organic chemical art. When the ketone (A) or (B) contains a tertiary aliphatic alcohol group (which is the case when either Y or Y² is hydroxy), this acylation is necessarily selective, but still, in general, is readily accomplished because of the greater activity of the phenolic group relative to the hindered tertiary, alcoholic group. The preferred methods borrow from coupling methods used in the synthesis of peptides. According to one of the preferred methods, a substantially molar equivalent of the acid is coupled with the phenolic ketone by the action of substantially one molar equivalent of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide. This coupling is generally carried out in a reaction-inert solvent such as methylene chloride in the presence of 10-20% molar excess of a tertiary amine such as 4-dimethylaminopyridine. Temperature is not critical, with temperatures in the range of 0-50°C being generally satisfactory, and ambient temperatures (generally about 17-27°C) preferred, since the cost of heating or cooling is avoided.

-10-

Alternatively, the compounds of the formulas (I) and (II) are obtained directly by acylation of the appropriate, known phenolic 1-alkanol compound of the above formulas (A) and (B) wherein A and B are taken
5 separately, A is hydrogen and B is hydroxy. Indeed, when the 1-alkanol is already available in resolved form, this is a preferred route to the optically active forms of the present esters.

The ketonic and 1-alkanol precursors of the
10 formulas (A) and (B) depicted above are disclosed in my Published International Patent Application Number WO 90/14087 cited above. In the ketones of that reference wherein the phenol group is protected, the
15 protecting group is removed by the same methods there particularly disclosed for the deprotection of phenol-protected 1-alkanol derivatives. Such a deprotection method is also specifically described in Preparations detailed below.

The inherent antiischemic activity and ability of
20 the present prodrug esters to block excitatory amino acid receptors is reflected from the study of the corresponding phenolic 1-alkanol compounds (of the above formulas (A) and (B) wherein A and B are taken
separately, A is hydrogen and B is hydroxy). These
25 biological methods are detailed in the prior art references cited above, viz., Gotti et al., Carter et al. and my published International application WO 90/14088.

The present prodrug esters are dosed at weight
30 levels which are chemically equivalent to the weight levels of the fully active phenolic forms, as detailed in my published International application WO 90/14088 cited above. For example, for a 10 mg dose of a phenol

-11-

having a molecular weight of 327, the amount of a prodrug ester having a molecular weight of 516 will be

$$10 \text{ mg} \times \frac{516}{327} = 15.8 \text{ mg}$$

5 The present prodrug esters are formulated into oral and parenteral dosage forms according to the same conventional methods which are used in the formulation of the corresponding phenols as described in my published International application WO 90/14088.

10 The present invention is illustrated by the following examples, but is not limited to the details thereof.

15 All non-aqueous reactions were run under nitrogen for convenience and generally to maximize yields. All solvents/diluents were dried according to standard published procedures or purchased in a predried form. All reactions were stirred either magnetically or mechanically. NMR spectra are recorded at 300 MHz and are reported in ppm. The NMR solvent was CDCl_3 unless other specified.

-12-

EXAMPLE 12-(4-Hydroxy-4-phenylpiperidino)-1-(4-(4-(morpholinomethyl)benzoyloxy)phenyl)-1-propanone

To a mixture of 4-(morpholinomethyl)benzoic acid
5 (3.17 g, 12.3 mmol), 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanone (4.0 g, 12.29 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (2.36 g, 12.31 mmol) in methylene chloride (75 mL) was added 4-dimethylaminopyridine
10 (1.88 g, 15.39 mmol). The heterogeneous mixture was allowed to stir overnight under a nitrogen atmosphere at ambient temperature. The mixture was washed with saturated aqueous bicarbonate (2 x 50 mL), dried by filtration through phase separating filter paper, and
15 concentrated to a glassy yellow solid. Trituration with ether and hexane yielded 5.17 g, 80% of a light yellow solid product which was suitable for further reaction without additional purification. A sample recrystallized from ethyl acetate/hexane had: m.p.
20 126-126.5°C; NMR (CDCl₃) 8.22 (d, J=8.6 Hz, 2H), 8.13 (d, J=7.8 Hz, 2H), 7.47 (t, J=7.3 Hz, 4H), 7.34-7.19 (m, 5H), 4.13 (q, J=6.6 Hz, 1H), 3.70 (t, J=4.4 Hz, 4H), 3.57 (s, 2H), 2.97-2.79 (m, 2H), 2.67-2.60 (m, 2H), 2.44 (t, J=4.5 Hz, 4H), 2.18-1.98 (m, 2H),
25 1.78-1.67 (m, 3H), 1.31 (d, J=6.6 Hz, 3H). IR (KBr) 3270, 2960, 2942, 2912, 2830, 2821, 1743, 1682, 1596, 1390, 1273, 1199.

Analysis calculated for C₃₂H₃₆N₂O₅:

C, 72.70; H, 6.86; N, 5.30.

30 Found:

C, 72.42; H, 6.65; N, 5.25.

In like manner, other phenol-ketones of the Preparation below are converted to:

2-(4-Benzyl-4-hydroxypiperidino)-1-(4-(4-morpholinomethyl)benzoyloxy)phenyl)-1-propanone; and

-13-

2-(4-(4-Chlorophenyl)-4-hydroxypiperidino)-1-(4-(morpholinomethyl)benzoyloxy)phenyl-1-propanone.

EXAMPLE 2

5 Racemic (1S*,2S*)- and (1R*,2S*)-2-(4-Hydroxy-4-phenylpiperidino)-1-(4-(4-(morpholinomethyl)benzoyloxy)phenyl)-1-propanol

Sodium borohydride (0.39 g, 10.3 mmol) was partially dissolved in absolute ethanol (25 mL) and chilled to 0°C and an ice cold ethanol solution (50 mL) of the title ketone product of the preceding Example (5.0 g, 9.46 mmol) was added over 2 minutes. The reaction was stirred at 0°C overnight, and then it was quenched with glacial acetic acid (6 mL). The volatiles were distilled from the reaction mixture under vacuum while maintaining the pot temperature at or below 0°C. The residual material was flash chromatographed on silica gel (2 x 6 inches, ethyl acetate/hexane gradient elution). No product was obtained. Continued elution with a methanol/ethyl acetate gradient gave 2.90 g of the (S*,S*)-title product, which was recrystallized from ethanol to give 1.8 g of purified (S*,S*)-title product: m.p. 172-173°C; NMR (CDCl₃) 8.17 (d, J=8.3 Hz, 2H), 7.56-7.25 (m, 9H), 7.20 (d, J=8.5 Hz, 2H), 4.33 (d, J=9.7 Hz, 1H), 3.73 (t, J=4.6 Hz, 4H), 3.59 (s, 2H), 3.11 (dt, J=1.7, 11.6 Hz, 1H), 2.76-2.59 (m, 4H), 2.47 (t, J=4.5 Hz, 4H), 2.31-2.07 (m, 3H), 1.85 (br d, J=13.2 Hz, 3H), 0.89 (d, J=6.7 Hz, 3H); IR (KBr) 3452, 3245, 2970, 2930, 2893, 1730, 1273, 1262, 1194, 1114, 1075, 797, 758.

30 Analysis calculated for C₃₂H₃₈N₂O₅:

C, 72.43; H, 7.22; N, 5.28.

Found:

C, 72.58; H, 6.95; N, 5.26.

-14-

Continued gradient elution with methanol/ethyl acetate gave 1.71 g of the (R*,S*)-title product as its acetate salt. It was further purified by recrystallization from ethanol/ether to give purified (R*,S*)-title product, 0.60 g of white powder: m.p. 164-165°C; NMR (DMSO-d₆) 8.10 (d, J=8.2 Hz, 2H), 7.54 (d, J=8.2 Hz, 2H), 7.45 (t, J=7.4 Hz, 4H), 7.31 (t, J=7.5 Hz, 2H), 7.21 (d, J=8.3 Hz, 3H), 5.82 (br s, 4H), 4.91 (d, J=4.1 Hz, 1H), 3.59 (t, J=4.6 Hz, 4H), 3.01-2.71 (m, 6H), 2.50 (m, 4H), 2.20-1.80 (m with s at 1.90 ppm, 5H), 1.64-1.60 (m, 2H), 1.01 (d, J=6.6 Hz, 3H). IR (KBr) 2961, 2856, 2820, 1733, 1268, 1201, 1071. Analysis calculated for C₃₂H₃₈N₂O₅·C₂H₄O₂:

C, 69.13; H, 7.17; N, 4.74.

15 Found:

C, 70.39; H, 6.85; N, 4.86.

By the same method, the additional products of the preceding Example are converted to:

(1S*,2S*)- and (1R*,2S*)-2-(4-Benzyl-4-hydroxypiperidino)-1-(4-(4-(morpholinomethyl)benzoyloxy)phenyl)-1-propanol; and
 (1S*,2S*)- and (1R*,2S*)-2-(4-(4-Chlorophenyl)-4-hydroxypiperidino)-1-(4-(4-(morpholinomethyl)benzoyloxy)phenyl)-1-propanol.

EXAMPLE 3

25 1-(4-(4-Diethylaminomethyl)benzoyloxy)phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanone

The coupling of 4-diethylaminomethylbenzoic acid with 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanone was carried out essentially as in Example 1. The crude product was treated with ether and hexane with stirring and yielded the creamy white product in 73% yield in a state of purity suitable for the reduction step. A sample recrystallized from

-15-

ether/hexane gave a white powder which had: m.p. 106-107°C; NMR (CDCl₃) 8.25 (d, J=8.8 Hz, 2H), 8.15 (d, J=8.3 Hz, 2H), 7.51 (t, J=7.2 Hz, 4H), 7.38-7.22 (m, 5H), 4.16 (q, J=6.7 Hz, 1H), 3.66 (s, 2H), 2.96-2.81 (m, 2H), 2.71-2.67 (m, 2H), 2.55 (q, J=7.1 Hz, 4H), 2.22-2.00 (m, 3H), 1.82-1.69 (m, 2H), 1.35 (d, J=6.7 Hz, 3H), 1.07 (t, J=7.1 Hz, 6H). IR (KBr) 3452, 2969, 2935, 2833, 1738, 1681, 1264, 1198, 1164, 1064.

Analysis calculated for C₃₂H₃₈N₂O₄

10 C, 74.68; H, 7.44; N, 5.44.

Found: C, 74.34; H, 7.28; N, 5.49.

In like manner, other phenol-ketones of the Preparation below are converted to:

15 1-(4-(4-(Diethylaminomethyl)benzoyloxy)phenyl)-2-(3-(phenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-propanone;

2-(3-(4-Chlorophenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-(4-diethylaminomethyl)benzoyloxy)phenyl)-1-propanone;

20 1-(4-(4-(Diethylaminomethyl)benzoyloxy)phenyl)-2-(3-(2-thienylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-propanone;

2-(3-Benzyl-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-(4-diethylaminoethyl)benzoyloxy)phenyl)-1-propanone; and

25 2-(3-Hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-(4-diethylaminoethyl)benzoyloxy)phenyl)-1-propanone.

EXAMPLE 4

30 Racemic (1S*,2S*)- and (1R*,2S*)-1-(4-Diethylaminomethyl)benzoyloxy)phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol

The title product from the preceding Example was reduced with sodium borohydride as in Example 2. Purification by silica gel chromatography and

-16-

recrystallization gave first (1S*,1S*)-title product (0.28 g, 28%) which had: m.p. 174-175°C (ethanol); NMR (CDCl₃) 8.14 (d, J=8.2 Hz, 2H), 7.50 (t, J=8.3 Hz, 4H), 7.43-7.35 (m, 4H), 7.27 (t, J=7.2 Hz, 1H), 7.18 (d, J=8.5 Hz, 2H), 4.31 (d, J=9.7 Hz, 1H), 3.64 (s, 2H), 3.08 (t, J=10.6 Hz, 1H), 2.72-2.60 (m, 4H), 2.53 (q, J=7.1 Hz, 4H), 2.27-2.05 (m, 2H), 1.92 (br s, 1H), 1.82 (br d, J=13.2 Hz, 2H), 1.05 (t, J=7.1 Hz, 6H), 0.87 (d, J=6.6 Hz, 3H); IR (KBr) 3399, 2973, 2947, 1727, 1610, 1271, 1258, 1202, 1078.

Analysis calculated for C₃₂H₄₀N₂O:

C, 74.39; H, 7.80; N, 5.42.

Found:

C, 74.31; H, 7.76; N, 5.38.

The second product isolated was the (1R*,1S*)-title product, as its acetate salt (0.119 g, 11%) which had: m.p. 148-150°C (ethanol); NMR (CDCl₃) 8.14 (d, J=8.3 Hz, 2H), 7.52-7.27 (m, 10H), 7.18 (d, J=8.6 Hz, 2H), 5.45 (d, J=2.4 Hz, 1H), 3.69 (s, 2H), 3.50 (br d, J=11.6 Hz, 1H), 3.27-3.22 (m, 2H), 3.12-3.03 (m, 2H), 2.57 (q, J=7.1 Hz, 4H), 2.50-2.39 (m, 2H), 2.04 (s, 3H), 1.87 (br t, J=13.6 Hz, 2H), 1.10-1.05 (m, 9H); IR (KBr) 3167, 2967, 2962, 1737, 1257, 1205, 1172, 1071.

Analysis calculated for C₃₂H₄₀N₂O₄·C₂H₄O₂:

C, 70.81; H, 7.69; N, 4.86.

Found:

C, 70.72; H, 7.64; N, 4.82.

The HCl salt of the (1S*,2S*)-title product recrystallized from ethanol/ether had: m.p. 180-184°C. Analysis calculated for C₃₂H₄₀N₂O₄·2HCl·0.5 H₂O:

C, 64.20; H, 7.24; N, 4.61.

Found:

C, 64.02; H, 7.29; N, 4.42.

By the same method the other products of the preceding Example are converted to:

-17-

(1S*,2S*)- and (1R*,2S*)-1-(4-(4-Diethylaminomethyl)-benzoyloxy)phenyl)-2-(3-(phenylthio-8-azabicyclo[3.2.1]-oct-8-yl)-1-propanol;

5 (1S*,2S*)- and (1R*,2S*)-2-(3-(4-Chlorophenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-(4-diethylaminomethyl)-benzoyloxy)phenyl-1-propanol;

(1S*,2S*)- and (1R*,2S*)-1-(4-(4-Diethylaminomethyl)-benzoyloxy)phenyl)-2-(2-(thienylthio)-8-azabicyclo[3.2.1]-oct-8-yl)-1-propanol;

10 (1S*,2S*)- and (1R*,2S*)-2-(3-Benzyl-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-(4-diethylaminoethyl)benzoyloxy)phenyl)-1-propanol; and

(1S*,2S*)- and (1R*,2S*)-2-(3-Hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-(4-diethylaminoethyl)-benzoyloxy)phenyl)-1-propanol.

15

EXAMPLES 5-10

Substituting an equivalent amount of benzoic acid or of the appropriately substituted benzoic acid for the 4-(morpholinomethyl)benzoic acid, the method of

20 Example 1 was used to prepare the following additional compounds:

5. 2-(4-Hydroxy-4-phenylpiperidino)-1-(4-(4-((1,1-dimethylethyl)aminomethyl)benzoyloxy)phenyl)-1-propanone; m.p. 156°C (hexane trituration, 47% yield).

25 6. 1-(4-(Benzoyloxy)phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanone.

7. 2-(4-Hydroxy-4-phenylpiperidino)-1-(4-(4-(piperidinomethyl)benzoyloxy)phenyl)-1-propanone.

8. 2-(4-Hydroxy-4-phenylpiperidino)-1-(4-(4-(2-methylpiperidinomethyl)benzoyloxy)phenyl)-1-propanone.

30 9. 2-(4-Hydroxy-4-phenylpiperidino)-1-(4-(4-(diethylaminomethyl)benzoyloxy)phenyl)-1-propanone.

-18-

10. 1-(4-(3-(Di thylaminomethyl)benzoyloxy)phenyl)-
2-(4-hydroxy-4-phenylpiperidino)-1-propanone.

EXAMPLE 11

5 Racemic (1S*,2S*)-2-(4-Hydroxy-4-phenyl-
 piperidino)-1-(4-((1,1-dimethylethyl)-
 aminomethyl)benzoyloxy)phenyl)-1-propanol

Lithium aluminum hydride (0.08 g, 2.11 mmol) was
slurried in dry tetrahydrofuran (12 mL) and chilled to
-78°C. The ketone product of Example 5 (0.44 g, 0.86
10 mmol) was added neat all at once to this cold slurry
followed by continued stirring at -78°C for 1 hour.
The mixture which had now become a gel was diluted with
tetrahydrofuran (10 mL) and quenched with acetic acid
(0.48 mL, 8.4 mmol). The solvent was removed at
15 reduced pressure and the residue was flash chromato-
graphed on silica gel (1 x 6 inches, packed in 30%
ethyl acetate/hexane). Ethyl acetate/hexane gradient
elution gave no product. Continued elution with 10%
methanol/ethyl acetate yielded the product as an actate
20 salt. This solid was suspended in ethyl acetate and
vigorously shaken with saturated sodium bicarbonate.
The phases were separated and the aqueous layer was
extracted twice with ethyl acetate. The combined organic
layer was dried over calcium sulfate and concentrated.
25 The residue was recrystallized from methanol to afford
30 mg (6.7%) of the title product as a white solid;
m.p. 195-197°C; NMR (CDCl₃) 8.15 (d, J=8.5 Hz, 2H),
7.53 (t, J=7 Hz, 4H), 7.48-7.24 (m, 5H), 7.20 (d, J=8.5
Hz, 2H), 4.34 (d, J=9.5 Hz, 1H), 3.85 (s, 2H), 3.13
30 (long range coupled t, J=10.5 Hz, 1H), 2.86-2.61 (m,
4H), 2.38-2.09 (sym m, 2H), 1.88 (br d, J=13.5 Hz, 2H),
1.38 (small impurity), 1.26 (s, 1H), 0.90 (d, J=6.5 Hz,
3H). One hydroxyl proton was not observed.

-19-

Analysis calculated for $C_{32}H_{40}N_2O_4$:

C, 74.39; H, 7.80; N, 5.42.

Found:

C, 73.98; H, 7.80; N, 5.18.

EXAMPLES 12-16

- 5 Using the ketone reduction procedures of the prior Examples, the ketones of Examples 6-10 were converted to the following racemic compounds:
- 12a. (1S*,2S*)-1-(4-(Benzoyloxy)phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol; 38% yield;
- 10 m.p. 166°C (from ethanol).
- 12b. (1R*,2S*)-1-(4-(Benzoyloxy)phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol; 17% yield;
- m.p. 188-191°C (from ethanol).
- 13a. (1S*,2S*)-2-(4-Hydroxy-4-phenylpiperidino)-
- 15 1-(4-(4-(piperidinomethyl)benzoyloxy)phenyl)-1-propanol; 29% yield; m.p. 175°C (dec), (from ethyl acetate).
- 13b. (1R*,2S*)-2-(4-Hydroxy-4-phenylpiperidino)-
- 1-(4-(4-(piperidinomethyl)benzoyloxy)phenyl)-1-propanol; 15% yield; m.p. 167°C (dec), (from ethyl acetate).
- 20 14a. (1S*,2S*)-2-(4-Hydroxy-4-phenylpiperidino)-
- 1-(4-(4-(2-methylpiperidinomethyl)benzoyloxy)phenyl)-1-propanol; 37% yield; m.p. 179°C (dec), (from ethyl acetate).
- 14b. (1R*,2S*)-2-(4-Hydroxy-4-phenylpiperidino)-
- 25 1-(4-(4-(2-methylpiperidinomethyl)benzoyloxy)phenyl)-1-propanol; 16% yield; m.p. 160°C (dec), (from ethyl acetate).
- 15a. (1S*,2S*)-2-(4-Hydroxy-4-phenylpiperidino)-
- 1-(4-(4-(2-dimethylaminomethyl)benzoyloxy)phenyl)-
- 30 1-propanol; 7% yield; m.p. 195-198°C (dec), (from methanol).

-20-

15b. (1R*,2S*)-2-(4-Hydroxy-4-phenylpiperidino)-1-(4-(4-(2-dimethylaminomethyl)benzoyloxy)phenyl)-1-propanol; 26% yield; m.p. 162-182°C (dec), (from ethyl acetate).

5 16. (1S*,2S*)-1-(4-(3-(Diethylaminomethyl)benzoyloxy)phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol; 14% yield; m.p. 119-123°C (from methylcyclohexane).

EXAMPLE 17

10 Racemic (1S*,2S*)-1-(4-(4-(Diethylaminomethyl)benzoyloxy)phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol.

Carbonyl diimidazole (0.25 g, 1.54 mmol) and racemic (1S*,2S*)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol hydrochloride (0.37 g, 1.52 mmol; Chenard, International Patent Application Publication No. WO 90/14088, Example 38 at page 42) in dry CH₂Cl₂ (10 ml) were stirred for 1 hour at ambient temperature. 4-(Diethylaminomethyl)benzoic acid (0.50 g, 1.53 mmol) was then added and the resulting mixture was stirred overnight. The reaction mixture was then washed with saturated NaHCO₃, H₂O and brine, dried with MgSO₄ and concentrated to give a white solid (0.41 g) which ¹HNMR (CDCl₃) showed to be a mixture of the acid, desired monoester and undesired diesterified material. Purification by silica gel flash chromatography (1 x 6 inches, ethyl acetate/hexane gradient for elution) gave 100 mg of crude title product as a colorless oil. This material was recrystallized from ethanol to yield purified title product (33 mg, 4.2%) having properties identical with those of the (1S*,2S*)-title product of Example 4.

30 By the same method, the enantiomeric (1S,2S)- and (1R,2R)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanols (WO 90/14088, Example 78 at page 47) are converted to the corresponding 4-(diethylaminomethyl)benzoate esters.

-21-

PREPARATION1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanone

1-(4-(Triisopropylsilyloxy)phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanone (International Application Publication Number: WO 90/14088, Example 36 at page 41; 22.0 g, 45.7 mmol) was dissolved in dry tetrahydrofuran (500 mL). Tetrabutylammonium fluoride (55 ml, 55 mmol, 1N in tetrahydrofuran) was added dropwise to the stirred solution over 3 minutes. After stirring for 1 hour, the reaction mixture was concentrated and the concentrate flash chromatographed on silica gel (3 x 6 inches). The column was gradiently eluted with ethyl acetate/hexane, then sequentially with 100% ethyl acetate, 1:9 methanol:ethyl acetate and finally with 1:5 methanol:ethyl acetate. Product-containing fractions were stripped to yield 16.7 g (100%) of title product as a light yellow solid which was triturated with hexane; m.p. 95-97°C; ¹H-NMR (CDCl₃) delta (ppm) 8.08 (d, J=8.5 Hz, 2H), 7.48 (d, J=8 Hz, 2H), 7.34 (t, J=8 Hz, 2H), 7.28-7.25 (m, 1H partially obscured by CHCl₃ from NMR solvent), 6.89 (d, J=8.5 Hz, 2H), 4.15 (q, J=7 Hz, 1H), 3.0-2.65 (m, 4H), 2.25-2.10 (m, 2H), 1.85-1.77 (m, 2H), 1.35 (d, J=7 Hz, 3H).

-22-


By the same method, other triisopropylsilyl protected ketones of said WO 90/14088 were converted to unprotected ketones as follows:

- 2-(4-Benzyl-4-hydroxypiperidino)-1-(4-hydroxy-phenyl)-1-propanone;
- 2-(4-(4-Chlorophenyl)-4-(hydroxypiperidino)-1-(4-hydroxyphenyl)-1-propanone;
- 1-(4-Hydroxyphenyl)-2-(3-(phenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-propanone;
- 2-(3-(4-Chlorophenylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-hydroxyphenyl)-1-propanone;
- 1-(4-Hydroxyphenyl)-2-(3-(2-thienylthio)-8-azabicyclo[3.2.1]oct-8-yl)-1-propanone;
- 2-(3-Benzyl-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)-1-(4-hydroxyphenyl)-1-propanone; and
- 1-(4-Hydroxyphenyl)-2-(3-hydroxy-3-phenyl-8-azabicyclo[3.2.1]oct-8-yl)-1-propanone.

-23-

CLAIMS


1. A compound of the formula



wherein

R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;


X is phenyl, benzyl, (C₁-C₃)alkoxy, phenoxy or one of said groups substituted on aromatic carbon by



p is 1 or 2;


R¹ and R² are taken separately and are each independently hydrogen or (C₁-C₆)alkyl, or R¹ and R² are taken together with the nitrogen to which they are attached to form a pyrrolidine, piperidine or morpholine ring, or one of said rings substituted by (C₁-C₃)alkyl;

Y and Y¹ are taken together and are




-24-

Y and Y¹ are taken separately and
Y is hydrogen or OH, and Y¹ is



Y is hydrogen and Y¹ is



n is 0, 1, 2 or 3;


m is 0, 1, 2, 3 or 4;

Q is S or CH=CH;


X¹ is hydrogen, (C₁-C₃)alkyl, (C₁-C₃)alkoxy or
halo; and

Z is O, S, SO or SO₂; or
a pharmaceutically-acceptable acid addition salt
thereof.

2. A compound of claim 1 wherein R is methyl
having 1S*,2S* relative stereochemistry:



3. A compound of claim 2 wherein X is phenyl or
phenyl substituted by a group



-25-


4. A compound of claim 3 wherein the group

$\text{X}-\overset{\text{O}}{\underset{\text{n}}{\text{C}}}-\text{O}-$ is substituted para to the 1-hydroxyalkyl group.

5. A compound of claim 4 wherein Y and Y¹ are taken separately.

6. A compound of claim 5 wherein X is phenyl.

7. A compound of claim 5 wherein X is



8. A compound of claim 7 wherein R¹ and R² are taken separately, and R¹ and R² are each methyl or ethyl, or R¹ is hydrogen and R² is 1,1-dimethylethyl.

9. A compound of claim 8 wherein R¹ and R² are each ethyl.


10. A compound of claim 9 wherein Y is H and Y¹ is phenylthio or 4-chlorophenylthio.

11. The compound of claim 9 wherein Y is H and Y¹ is 2-thienylthio.

12. A compound of claim 9 wherein Y is OH and Y¹ is phenyl or benzyl.

13. A compound of claim 7 wherein R¹ and R² are taken together with the nitrogen to which they are attached to form a morpholine, a piperidine or a 2-methylpiperidine ring.


14. A compound of claim 4 wherein X is



-26-


15. A compound of claim 14 wherein R^1 and R^2 are taken separately and are each ethyl.

16. A compound of the formula




wherein

E is



R is H, (C_1-C_6) alkyl, (C_2-C_6) alkenyl or (C_2-C_6) alkynyl;

X is phenyl, benzyl, (C_1-C_3) alkoxy, phenoxy or one of said groups substituted on aromatic carbon by




p is 1 or 2;


R^1 and R^2 are taken separately and are each independently hydrogen or (C_1-C_6) alkyl, or R^1 and R^2 are taken together with the nitrogen to which they are attached to form a pyrrolidine, piperidine or morpholine ring, or one of said rings substituted by (C_1-C_3) alkyl;

Y^2 and Y^3 are taken together and are


-27-



Y^2 and Y^3 are taken separately, and Y^2 is OH
and Y^3 is



Y^9 is




n is 0, 1, 2 or 3;

m is 0, 1, 2, 3 or 4;

Q is S or CH=CH; and


X^1 is hydrogen, (C_1-C_3) alkyl, (C_1-C_3) alkoxy or halo; or a pharmaceutically-acceptable acid addition salt thereof.

17. A compound of claim 16 wherein R is methyl having 1S*,2S* relative stereochemistry:




-28-

18. A compound of claim 17 wherein X is phenyl or phenyl substituted by a group



19. A compound of claim 18 wherein the group
 $\begin{array}{c} O \\ || \\ X-C-O- \end{array}$ is substituted para to the 1-hydroxyalkyl group.

20. A compound of claim 19 wherein E is




and Y^2 and Y^3 are taken separately.

21. A compound of claim 20 wherein X is phenyl.

22. The compound of claim 21 wherein Y^2 is OH and Y^3 is phenyl.

23. A compound of claim 20 wherein X is



24. A compound of claim 23 wherein R^1 and R^2 are taken separately, and R^1 and R^2 are each methyl or ethyl, or R^1 is hydrogen and R^2 is 1,1-dimethylethyl.

25. The compound of claim 24 wherein R^1 and R^2 are each methyl, Y^2 is OH and Y^3 is phenyl.

26. The compound of claim 24 wherein R^1 and R^2 are each ethyl, Y^2 is OH and Y^3 is phenyl.

27. The compound of claim 24 wherein R^1 is hydrogen and R^2 is 1,1-dimethylethyl, Y^2 is OH and Y^3 is phenyl.

-29-


28. A compound of claim 23 wherein R^1 and R^2 are taken together with the nitrogen to which they are attached to form a morpholine, a piperidine or a 2-methylpiperidine ring.

29. The compound of claim 28 wherein R^1 and R^2 are taken together with the nitrogen to which they are attached to form a morpholine ring, Y^2 is OH and Y^3 is phenyl.

30. The compound of claim 28 wherein R^1 and R^2 are taken together with the nitrogen to which they are attached to form a piperidine ring, Y^2 is OH and Y^3 is phenyl.

31. The compound of claim 28 wherein R^1 and R^2 are taken together with the nitrogen to which they are attached to form a 2-methylpiperidine ring, Y^2 is OH and Y^3 is phenyl.

32. A compound of claim 20 wherein X is



33. The compound of claim 32 wherein R^1 and R^2 are taken separately and are each ethyl, Y^2 is OH and Y^3 is phenyl.

34. A pharmaceutical composition comprising a neuroprotective amount of a compound of claim 1 and a pharmaceutically-acceptable carrier.


35. A pharmaceutical composition comprising a neuroprotective amount of a compound of claim 16 and a pharmaceutically-acceptable carrier.

-30-

36. A method of treating stroke, traumatic head injury or a CNS degenerative disease in man which comprises treatment with a neuroprotective amount of a compound of claim 1.

37. A method of treating stroke, traumatic head injury or a CNS degenerative disease in man which comprises treatment with a neuroprotective amount of a compound of claim 16.


38. A compound of the formula



wherein

R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

X is phenyl, benzyl, (C₁-C₃)alkoxy, phenoxy or one of said groups substituted on aromatic carbon by




p is 1 or 2;


R¹ and R² are taken separately and are each independently hydrogen or (C₁-C₆)alkyl, or R¹ and R² are taken together with the nitrogen to which they are attached to form a pyrrolidine, piperidine or morpholine ring, or one of said rings substituted by (C₁-C₃)alkyl;

-31-


Y and Y¹ are taken together and are



Y and Y¹ are taken separately and
Y is hydrogen or OH, and Y¹ is



Y is hydrogen and Y¹ is



n is 0, 1, 2 or 3;


m is 0, 1, 2, 3 or 4;

Q is S or CH=CH;

X¹ is hydrogen, (C₁-C₃)alkyl, (C₁-C₃)alkoxy or halo; and

Z is O, S, SO or SO₂.

39. A compound of the formula




--- (IV)

-32-


wherein

E is



R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;


X is phenyl, benzyl, (C₁-C₃)alkoxy, phenoxy or one of said groups substituted on aromatic carbon by




p is 1 or 2;

R¹ and R² are taken separately and are each independently hydrogen or (C₁-C₆)alkyl, or R¹ and R² are taken together with the nitrogen to which they are attached to form a pyrrolidine, piperidine or morpholine ring, or one of said rings substituted by (C₁-C₃)alkyl;


Y² and Y³ are taken together and are



Y² and Y³ are taken separately, and Y² is OH and Y³ is



-33-


 Y^9 is n is 0, 1, 2 or 3; m is 0, 1, 2, 3 or 4; Q is S or $CH=CH$; and X^1 is hydrogen, (C_1-C_3) alkyl, (C_1-C_3) alkoxy or halo.

-34-

5

40. A process for preparing a compound of the formula

10




15

wherein

R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

X is phenyl, benzyl, (C₁-C₃)alkoxy, phenoxy or one of said groups substituted

20 on aromatic carbon by




25

p is 1 or 2;

R¹ and R² are taken separately and are each independently hydrogen or (C₁-C₆)alkyl, or R¹ and R² are taken together with the nitrogen to which they are attached to form a pyrrolidine, piperidine or morpholine ring, or one of said rings

30 substituted by (C₁-C₃)alkyl;

Y and Y¹ are taken together and are




35

-35-

Y and Y' are taken separately and


Y is hydrogen or OH, and Y' is

5



Y is hydrogen and Y' is

10



n is 0, 1, 2 or 3;


m is 0, 1, 2, 3 or 4;

Q is S or CH=CH;

15

X¹ is hydrogen, (C₁-C₃)alkyl, (C₁-C₃)alkoxy or halo; andZ is O, S, SO or SO₂ comprising reacting a compound of the formula

20



wherein


R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

25

A and B are taken together and are oxygen (forming a carbonyl with the carbon atom);

X is phenyl, benzyl, (C₁-C₃)alkoxy, phenoxy or one of said groups substituted on aromatic carbon by

30



p is 1 or 2;


R¹ and R² are taken separately and are each independently hydrogen or

-36-

(C₁-C₆)alkyl, or R¹ and R² are taken together with the nitrogen to which they are attached to form a pyrrolidine, piperidine or morpholine ring, or one of said rings substituted by (C₁-C₃)alkyl;

Y and Y¹ are taken together and are


5



Y and Y¹ are taken separately and


10

Y is hydrogen or -OH, and Y¹ is



15

Y is hydrogen and Y¹ is



20

n is 0, 1, 2 or 3;

m is 0, 1, 2, 3 or 4;

Q¹ is S or -CH=CH-;


X¹ is hydrogen, (C₁-C₃)alkyl, (C₁-C₃)alkoxy or halo; and

Z is O, S, SO or SO₂ with an excess of a hydride reducing agent in a reaction

25 inert solvent at about -78°C to about 0°C for about 15 minutes to about 24 hours.

41. The process according to claim 1 comprising the additional prior step of reacting a compound of the formula

30




-37-

wherein

R is H, (C₁-C₆) alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

A and B are taken together and are oxygen (forming a carbonyl with the carbon atom);


5 Y and Y' taken together and are



10


Y and Y' are taken separately and

Y is hydrogen or OH, and Y' is



15

Y is hydrogen and Y' is



20


n is 0, 1, 2 or 3;

25 m is 0, 1, 2, 3 or 4;

Q is S or CH=CH;

X¹ is hydrogen, (C₁-C₃)alkyl, (C₁-C₃)alkoxy or halo; andZ is O, S, SO or SO₂ with an organic acid of the formula X-COOH, wherein X is phenyl, benzyl, (C₁-C₃)alkoxy, phenoxy or one of said groups substituted on

30 aromatic carbon by



-38-

taken separately and are each independently hydrogen or (C₁-C₆)alkyl, or R¹ and R² are taken together with nitrogen to which they are attached to form a pyrrolidine, piperidine or morpholine ring, or one of said rings substituted by (C₁-C₃)alkyl); and p


5 is 1 or 2 in the presence of an esterifying agent in a reaction inert solvent at a temperature of about 0°C to about 50°C for about 15 minutes to about 24 hours.

42. The process according to claim 41 wherein the esterifying agent is a peptide coupling reagent.

43. The process according to claim 42 wherein the peptide coupling reagent is 1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimide and additionally comprising adding
10 triethylamine.


44. The process according to claim 43 wherein the hydride reducing agent is sodium borohydride.

45. A process for preparing a compound of the formula



20 wherein


E is



R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

X is phenyl, benzyl, (C₁-C₃)alkoxy, phenoxy or one of said groups substituted
on aromatic carbon by

30




p is 1 or 2;


-39-

R¹ and R² are taken separately and are each independently hydrogen or (C₁-C₆)alkyl, or R¹ and R² are taken together with the nitrogen to which they are attached to form a pyrrolidine, piperidine or morpholine ring, or one of said rings substituted by (C₁-C₃)alkyl;


5 Y² and Y³ are taken together and are



10 Y² and Y³ are taken separately, and Y² is OH and Y³ is



15 Y³ is




20 n is 0, 1, 2 or 3;

m is 0, 1, 2, 3 or 4;

Q is S or CH=CH; and

X¹ is hydrogen, (C₁-C₃)alkyl, (C₁-C₃)alkoxy or halo comprising reacting a compound of the formula

25




30

-40-


wherein

E is

R is H, (C₁-C₈)alkyl, (C₂-C₈)alkenyl or (C₂-C₈)alkynyl;

A and B are taken together and are oxygen (forming a carbonyl with the oxygen atom);

10 X is phenyl, benzyl (C₁-C₃)alkoxy, phenoxy or one of said groups substituted on aromatic carbon by





15


p is 1 or 2;

R¹ and R² are taken separately and are each independently hydrogen or (C₁-C₆)alkyl, or R¹ and R² are taken together with the nitrogen to which they are attached to form a pyrrolidine, piperidine or morpholine ring, or one of said rings substituted by (C₁-C₃)alkyl;

20

Y² and Y³ are taken together and areY² and Y³ are taken separately, and Y² is OH and Y³ is

-41-

Y⁹ is

5

n is 0, 1, 2 or 3;

m is 0, 1, 2, 3 or 4;


Q is S or CH=CH; and

X¹ is hydrogen, (C₁-C₃)alkyl, (C₁-C₃)alkoxy or halo with an excess of a

10 hydride reducing agent in a reaction inert solvent at about -78°C to about 0°C for about 15 minutes to about 24 hours.

46. The process according to claim 45 comprising the additional prior step of reacting a compound of the formula

15




20

wherein

E is


25

R is H, (C₁-C₆)alkyl, (C₂-C₆)alkenyl or (C₂-C₆)alkynyl;

30 A and B are taken together and are oxygen (forming a carbonyl with the carbon atom);


-42-

Y² and Y³ are taken together and are




5

Y² and Y³ are taken separately, and Y² is OH and Y³ is



10

Y³ is



15

n is 0, 1, 2 or 3;


20

m is 0, 1, 2, 3 or 4;

Q is S or CH=CH; and

X¹ is hydrogen, (C₁-C₃)alkyl, (C₁-C₃)alkoxy or halo with an organic acid of the formula X-COOH, wherein X is phenyl, benzyl, (C₁-C₃)alkoxy, phenoxy or one of said groups substituted on aromatic carbon by

25



wherein R¹ and R² are taken separately and are each independently hydrogen or (C₁-C₆)alkyl, or R¹ and R² are taken together with nitrogen to which they are attached to form a pyrrolidin, piperidin or morpholine ring, or one of said rings substituted by (C₁-C₃)alkyl; and p is 1 or 2 in the presence of an esterifying agent in a reaction inert solvent at a temperature of about 0°C to about 50°C for about 15 minutes to about 24 hours.

30

-43-

47. The process according to claim 46 wherein the esterifying agent is a peptide coupling reagent.

48. The process according to claim 47 wherein the peptide coupling reagent is 1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimide and additionally comprising adding
5 triethylamine.

49. The process according to claim 48 wherein the hydride reducing agent is sodium borohydride.

INTERNATIONAL SEARCH REPORT

PCT/US 92/02131

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 C07D451/02; C07D211/04;	A61K31/33; C07D211/68;	C07D451/06; C07D409/02
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07D ; A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	WO,A,9 014 088 (PFIZER) 29 November 1990 cited by the Applicant see the whole document ---	1-49
X	WO,A,9 014 087 (PFIZER) 29 November 1990 cited by Applicant see the whole document ---	1-49
P,Y	EP,A,0 441 506 (PFIZER) 14 August 1991 see the whole document ---	1-49
P,Y	WO,A,9 117 156 (PFIZER) 14 November 1991 see the whole document ---	1-49
	-/-	
<p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
22 JULY 1992	19.08.92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	GETTINS M.P. <i>W. M. Gettins</i>	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	<p>JOURNAL OF MEDICINAL CHEMISTRY vol. 32, no. 12, December 1989, USA pages 2503 - 2507; BUNDGAARD ET AL: 'A novel solution-stable, water-prodrug Type' cited by applicant</p> <p>---</p>	1-49

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. US 9202131
SA 59848**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 22/07/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9014088	29-11-90	WO-A- 9014087	29-11-90
		CA-A- 2016860	17-11-90
		EP-A- 0398578	22-11-90
WO-A-9014087	29-11-90	CA-A- 2016860	17-11-90
		EP-A- 0398578	22-11-90
		WO-A- 9014088	29-11-90
EP-A-0441506	14-08-91	WO-A- 9112005	22-08-91
		DE-U- 9101346	06-06-91
WO-A-9117156	14-11-91	AU-A- 7456591	27-11-91
		CN-A- 1056497	27-11-91

FORM P079